Breath Test, Gastrointestinal Symptoms
Conditions
Keywords
Lactose maldigestion, gastrointestinal, Single-nucleotide polymorphism, probiotic
Brief summary
The main objective of the study is to investigate the effect of probiotic supplementation on lactose maldigestion.
Detailed description
Primary endpoint is defined as the difference in breath hydrogen concentration (BHC, ppm) in lactase and probiotic groups compared to placebo and non-inferiority in breath hydrogen concentration (BHC, ppm) in probiotic group compared to lactase group, measured by the incremental area under curve (iAUC) analysis. To characterize the benefit of the investigational product (IP) the following secondary endpoints will be analyzed: Breath test: * Breath hydrogen peak value (ppm) in lactase and probiotic groups compared to placebo * Cumulative breath hydrogen (ppm) in lactase and probiotic groups compared to placebo Acute gastrointestinal symptoms (severity or presence/absence to be defined on a Likert scale) in lactase and probiotic groups compared to placebo: * Abdominal pain * Flatulence * Bloating * Nausea and vomiting * Bowel movements and diarrhea (if present, stool consistency to be defined on Bristol stool scale and number of bowel movements to be recorded) Ancillary: * Baseline fasting BHC (ppm) * Breath methane (CH4; ppm) * Breath carbon dioxide (CO2; ppm) * Probiotic identification in feces before each lactose challenge by molecular methods * Gene test to determine lactase deficiency status at V1 (following single nucleotide polymorphism (SNP) variants to be screened: -13910\*C (Europe, Central Asia, commonly used) -13915\*T (Saudi-Arabia, Africa), -14010\*C (Africa), -13907\*C (Africa))
Interventions
DIETARY_SUPPLEMENTProbiotic
\- 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
DIETARY_SUPPLEMENTLactrase
\- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
OTHERPlacebo
\- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
Sponsors
Analyze & Realize
Danisco
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Crossover Assignment Randomized, double-blind, placebo-controlled, parallel-group study
Eligibility
Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntary, written, informed consent to participate in the study 2. Agreement to comply with the protocol and study restrictions 3. Healthy females and males of age 25 to 60 years (inclusive) 4. Self-declared or medically diagnosed lactose intolerance 5. Increase of more than 20 ppm in breath hydrogen within 3 h from the baseline fasting breath hydrogen value at V2 6. Participants who agree to maintain their usual dietary habits throughout the trial period 7. Participants who agree not to consume probiotics, prebiotics, fermented milk, and/or yogurt containing probiotics during and two weeks before Visit 3 (2 weeks after pre-screening visit) 8. Females of child-bearing potential who agree to use a medically approved methods of birth control 9. Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects 10. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research
Exclusion criteria
1. Gastrointestinal disorder or disease (e.g. Crohn's disease, ulcer, irritable bowel syndrome (IBS), Celiac disease, small intestinal bacterial overgrowth (SIBO), pancreatitis and disorders affecting gastrointestinal motility) 2. Diagnosed type 1 or type 2 diabetes 3. Prior abdominal surgery that, in the opinion of the investigator, may present a risk for the participant or affect study results 4. Ongoing or recent (last 1 months) antibiotic treatment. 5. Use of laxatives or drugs known to affect gut motility 1 month preceding the screening visit and during the study 6. Ongoing or recurrent use of proton pump inhibitors 7. Colonoscopy within 3 months before screening 8. History of recurrent colon cleansing and/or a colon cleansing within 3 months before screening 9. Gastrointestinal infection within 1 month before screening or during the trial 10. Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may affect the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness) 11. History of diagnosed coronary heart disease/cardiovascular disease or artificial heart valve. 12. Any obstructive or restrictive respiratory syndrome/disease that may impact breath test (e.g. asthma or chronic obstructive pulmonary disease (COPD)) 13. Use of tobacco, snuff, nicotine and e-cigarette 14. History of or current abuse of drugs, alcohol or medication (self- reported) 15. Self-declared use of illicit drugs 16. Pregnant or lactating female, or pregnancy planned during study period 17. Participants under administrative or legal supervision. 18. Participation in another study with any investigational product within 60 days of screening 19. Abnormal values in safety blood tests at V1 i.e. clinically significant or \>2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome) 20. Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by the iAUC analysis | approximately 40 days |
| Non-inferiority in breath hydrogen concentration (BHC, ppm) of probiotic group compared to lactase group (positive control), measured by the iAUC analysis | approximately 40 days |
| Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by the iAUC analysis | approximately 40 days |
Secondary
| Measure | Time frame |
|---|---|
| Difference in the severity of abdominal pain in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of nausea in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the presence of vomiting in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the presence of vomiting in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the presence of bowel movements in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the presence of bowel movements in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of flatulence in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by breath hydrogen peak value | approximately 40 days |
| Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by breath hydrogen peak value | approximately 40 days |
| Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by cumulative breath hydrogen value | approximately 40 days |
| Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by cumulative breath hydrogen value | approximately 40 days |
| Difference in the presence of diarrhea in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the presence of diarrhea in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of abdominal pain in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of flatulence in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of bloating in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of bloating in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
| Difference in the severity of nausea in lactase group compared to placebo, as defined by the gastrointestinal symptom survey | approximately 40 days |
Other
| Measure | Time frame |
|---|---|
| Description of the SNP variants in each treatment group | approximately 40 days |
| Difference in baseline fasting BHC (ppm) between the treatments | approximately 40 days |
| Difference in the quantity of probiotic in fecal samples between the treatments | approximately 40 days |
| Difference in breath carbon dioxide concentration (ppm) between the treatments | approximately 40 days |
| Difference in breath methane concentration (ppm) between the treatments | approximately 40 days |
Countries
Germany
Outcome results
None listed